超声联合NCE-MRA评价尿毒症透析功能及对FGF-23、klotho的鉴定分析

doi:10.7517/issn.1674-0475.220204

摘要/Abstract

摘要： 本文探讨超声联合非对比增强磁共振血管造影（NCE-MRA）评价尿毒症透析患者心血管钙化、左心室内功能及对成纤维细胞生长因子-23（FGF-23）、klotho的鉴定。收集肾内科血液透析中心56例血液透析治疗患者临床资料，超声联合NCE-MRA评价尿毒症透析功能；酶联免疫法测定血清FGF-23、klotho的含量。结果显示：（1）左心室功能显示，与透析前相比，透析后尿毒症患者左室射血分数（LVEF）、左心室舒张末容积（LVEDV）、左心室16节段收缩失同步指数（SDI16）、左心室16节段舒张失同步指数（DDI16）均显著增加（P<0.05）；（2）血清FGF-23水平与血肌酐、碱性磷酸酶、磷、钙等含量呈正相关（P<0.05），与残余肾功能、尿素清除指数、klotho蛋白含量等呈负相关（P<0.05）。本研究发现，血液透析可以显著改善尿毒症患者心室内功能，血清FGF-23和klotho蛋白可用于诊断尿毒症透析心血管钙化情况。

关键词: 超声, NCE-MRA评价, 尿毒症透析, 心血管钙化, 心室内功能, 成纤维细胞生长因子-23, 可溶性klotho蛋白

Abstract: The purpose of this paper was to evaluate cardiovascular calcification, left ventricular function and identification of serum standard FGF-23 (fibroblast growth factor-23) and klotho of uremic dialysis patients as the combination of ultrasound with contrast enhanced magnetic resonance angiography (NCE-MRA). The clinical data of 56 patients undergoing hemodialysis treatment were collected to evaluate the dialysis function of uremia content through ultrasound combined with NCE-MRA was used. The results showed:(1) compared with before dialysis the left ventricular function showed that, the left ventricular ejection fraction (LVEF), diastolic volume (LVEDV), systolic dyssynchrony index (SDI16), and diastolic dyssynchrony index (DDI16) of uremic patients after dialysis were significantly increased (P<0.05); (2) the level of serum standard FGF-23 was positively correlated with the contents of creatinine, alkaline phosphatase, phosphorus, calcium, etc. (P<0.05), and was positively correlated with residual renal function, urea clearance index, the protein content of klotho was negatively correlated (P<0.05). This study found that hemodialysis could significantly improve the intraventricular function of uremic patients; serum FGF-23 and klotho protein could be used to diagnose cardiovascular calcification in uremic dialysis patients.

Key words: ultrasound, NCE-MRA evaluation, uremic dialysis, cardiovascular calcification, ventricular function, fibroblast growth factor-23, soluble klotho protein

刘红, 黄俊波, 万磊. 超声联合NCE-MRA评价尿毒症透析功能及对FGF-23、klotho的鉴定分析[J]. 影像科学与光化学, 2022, 40(4): 848-853.

LIU Hong, HUANG Junbo, WAN Lei. Ultrasound Combined with NCE-MRA to Evaluate the Dialysis Function of Uremia and the Identification Analysis of Serum FGF-23 and klotho[J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2022, 40(4): 848-853.

参考文献

[1] Tangren J, Nadel M, Hladunewich M A. Pregnancy and end-stage renal disease[J]. Blood Purification, 2018,45(1-3):194-200.
[2] Shen Y J, Cai R R, Sun J, et al. Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men:A systematic review and meta-analysis[J]. Endocrine, 2017,55(1):66-76.
[3] Khan S, Rosner M H. Peritoneal dialysis for patients with end-stage renal disease and liver cirrhosis[J]. Peritoneal Dialysis International, 2018,38(6):397-401.
[4] Bansal N. Evolution of cardiovascular disease during the transition to end-stage renal disease[J]. Seminars in Nephrology, 2017,37(2):120-131.
[5] Hruska KA, Sugatani T, Agapova O, et al. The chronic kidney disease-mineral bone disorder (ckd-mbd):Advances in pathophysiology[J]. Bone, 2017,100:80-86.
[6] Zand L, Kumar R. The use of vitamin d metabolites and analogues in the treatment of chronic kidney disease[J]. Endocrinology and Metabolism Clinics of North America, 2017,46(4):983-1007.
[7] Su G B, Liu Z Z, Qin X D, et al. Vitamin D deficiency and treatment versus risk of infection in end-stage renal disease patients under dialysis:A systematic review and meta-analy-sis[J]. Nephrology Dialysis Transplantation, 2018,34(1):146-156.
[8] Xu L, Hu X S, Chen W L. Fibroblast growth factor-23 correlates with advanced disease conditions and predicts high risk of major adverse cardiac and cerebral events in end-stage renal disease patients undergoing continuous ambulatory peritoneal dialysis[J]. Journal of Nephrology, 2019,32(2):307-314.
[9] Quarles L D. Fibroblast growth factor 23 and a-Klotho co-dependent and independent functions[J]. Current Opinion in Nephrology and Hypertension, 2019,28(1):16-25.
[10] Takashi Y, Fukumoto S. Phosphate-sensing and regulatory mechanism of FGF23 production[J]. Journal of Endocrinological Investigation, 2020,43(7):877-883.
[11] 张淑芳, 梁震, 张红梅, 等. 维持性血液透析患者血管钙化危险因素分析[J]. 华北理工大学学报(医学版), 2016,18(4):294-298.
[12] Inampudi C, Alvarez P, Asleh R, et al. Therapeutic approach to patients with heart failure with reduced ejection fraction and end-stage renal disease[J]. Current Cardiology Reviews, 2018,14(1):60-66.
[13] Jiang Z, Tang Y, Yang L C, et al. Effect of restricted protein diet supplemented with keto analogues in end-stage renal disease:A systematic review and meta-analysis[J]. International Urology and Nephrology, 2018,50(4):687-694.
[14] Wald R, Thorpe K E, Walsh M W. Leveraging pragmatic clinical trial design to advance phosphate management in end-stage renal disease[J]. Current Opinion in Nephrology and Hypertension, 2019,28(1):34-39.
[15] Edmonston D L, Isakova T, Dember L M, et al. Design and rationale of hilo:A pragmatic, randomized trial of phosphate management for patients receiving maintenance hemodialy-sis[J]. American Journal of Kidney Diseases, 2021,77(6):920-930.
[16] Lundquist A L, Nigwekar S U. Optimal management of bone mineral disorders in chronic kidney disease and end stage renal disease[J]. Current Opinion in Nephrology and Hypertension, 2016,25(2):120-126.
[17] Joshi S, Shah S, Kalantar-Zadeh K. Adequacy of plant-based proteins in chronic kidney disease[J]. Joural of Renal Nutrition, 2019,29(2):112-117.
[18] Razaq S, Nigar F, Naqvi S H. Ultrasonographic diagnosis of tumoral calcinosis in end-stage renal disease[J]. Journal of the College of Physicians and Surgeons Pakistan:JCPSP, 2018,28(8):640-642.
[19] Block G A, Rosenbaum D P, Yan A, et al. Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis:A randomized phase 3 trial[J]. Journal of the American Society of Nephrology, 2019,30(4):641-652.
[20] Voelkl J, Tuffaha R, Luong T T D, et al. Zinc Inhibits phosphate-induced vascular calcification through TNFAIP3-mediated suppression of NF-κB[J]. Journal of the American Society of Nephrology:JASN, 2018,29(6):1636-1648.
[21] Milazi M, Douglas C, Bonner A. A bundled phosphate control intervention (4Ds) for adults with end-stage kidney disease receiving haemodialysis:A cluster randomized controlled trial[J]. Journal of Advanced Nursing, 2021,77(3):1345-1356.